# OnCo record psivac (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/psivac/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "psivac" ;
  schema:name "PsiVac"@en ;
  schema:alternateName "PsiVac Ltd"@en ;
  schema:description "PsiVac is a London company developing Ixovex-1, a genetically modified cold virus (adenovirus) designed to infect and burst cancer cells while largely sparing normal cells, and to rouse the immune system. It is in an early trial, alone and with the immunotherapy pembrolizumab."@en ;
  schema:url <https://onco.cc/companies/psivac/>, <https://www.psivac.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.psivac.com/> ;
  schema:addressCountry "GB" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/oncolytic-virus/> ;
  onco:trials <https://onco.cc/trials/nct06549946/> .